Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81
Document › Details

Autolus Therapeutics Ltd.. (3/5/18). "Press Release: Autolus Announces Confidential Submission of Draft Registration Statement for Potential Initial Public Offering in the United States". London.

Region Region United States (USA)
Organisations Organisation Autolus Therapeutics Ltd.
  Today Autolus Therapeutics plc (Nasdaq: AUTL)
  Group Autolus Therapeutics plc (Nasdaq: AUTL)
  Organisation 2 Securities and Exchange Commission (SEC) (US)
  Group United States (govt)
Products Product T cell therapy
  Product 2 investment banking
Index term Index term Autolus–SEVERAL: investment, 201803–201806 US IPO $150m+$22.5m with 8.824m+1.324m ADSs at $17/ADS at Nasdaq Global Select Market
Person Person Wilson, Julia (JW Communications 201209– before Vectura Group)

Autolus Limited, a U.K.-based biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today announced the confidential submission of a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission relating to a potential initial public offering of ordinary shares in the United States. The timing and the terms of this potential initial public offering have not yet been determined and are subject to market conditions and other factors.

This announcement is being made pursuant to and in accordance with Rule 135 under the U.S. Securities Act of 1933, as amended, and does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

- Ends -

Media Contact

JW Communications
Julia Wilson
+44 (0)7818 430877

Record changed: 2018-06-14


Picture ConsulTech GmbH RnD Credit Germany 650x80px

More documents for Autolus Therapeutics plc (Nasdaq: AUTL)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81

» top